News

In accordance with a licensing and distribution agreement with Par Pharmaceutical Companies, Par began immediate shipments of the 150mg strength tablets after the approval of another generic product,

The drug is a half-dose version of the Roche prescription drug Xenical which works by reducing the amount of fat the body absorbs from food. Undigested fat is

When administered on either a weekly schedule, five out of ten patients in the 50mg/m2 and 60mg/m2 dose cohorts experienced bone marrow blast reductions of more than 95%,

A pharmacokinetic analysis of three patients in the highest dose cohort of 160mg/m2 has shown transient peak plasma concentrations of approximately 10ug/ml. This and other data indicate that

The drug, VB6-845, is a humanized antibody fragment targeting EpCAM fused with the company's proprietary deimmunized form of the cytotoxic protein Bouganin. The phase I dose-escalation trial will

The regulator said that although Sanofi-Aventis' clinical trials showed that patients who took the treatment daily experienced significant weight loss after two years, there were a number of

Barr Laboratories dropped the patent litigation after the trial court found in favor of Eli Lilly on the patent in a suit against Zenith Goldline Pharmaceuticals, Teva Pharmaceuticals

Financial terms of the agreement were not disclosed. Idiopathic pulmonary fibrosis (IPF), a type of pulmonary fibrosis, is a progressive disorder affecting approximately 200,000 Americans and over five

The double-blind, placebo-controlled trial will take place at seven sites in the US, enrolling up to 150 female MS patients who have been recently diagnosed with relapsing-remitting MS.